摘要
了解干扰素α2b与苦参素、胸腺肽α1联合治疗慢性乙型肝炎的实验研究。98例HBeAg阳性的慢性乙型肝炎患者随机分成治疗组和对照组。治疗组49例,同时使用干扰素α2b与苦参素、胸腺肽a1 13周,随后使用干扰素α2b及胸腺肽α1 13周,最后单用干扰素α2b 26周;对照组49例单用同样剂量干扰素α2b 52周。疗程中定期检测血常规、丙氨酸转氨酶(ALT)、HBeAg、抗-HBe、HBVDNA、透明质酸酶(HA)。全部患者完成1年治疗。治疗组 ALT、HA复常率、HBeAg／抗-HBe血清转换率、HBVDNA阴转率明显高于对照组(分别为81．6％和53．1％,P< 0．005;44．9％和22．4％,P<0．025;42．9％和20．4％,P<0．025:79．6％和51．0％,P<0．005)。干扰素α2b与苦参素、胸腺肽α1联合治疗慢性乙型肝炎疗效优于单用干扰素α2b。
To evaluate the experimental efficacy of interferon α2b comibined with marine and thymosin al. 98 chronic hepatits B patients were enrolled and randomized into the therapy group and the control group. 49 cases in the therapy group received interferon α2b and thymosin α1 for 13weeks, at last interferon α2b simultaneously for 26 weeks; 49 cases in the control group received interferon α2b alone for 52 weeks. During the treatment blood routine examination ALT, HBeAg, Anti - HBe, HBVDNA and HA were termly checked and measured. All 98 patients completed the study. The rates for ALT and HA to recover to mormal and the rates for HBeAg and HBVDNA to change to be negative in combination group were superior to those in interferon α2b group. （81.6% vs 53.1%, P 〈 0.005;44.9% vs 22.4%, P 〈 0.0025;42.9% vs 20.4%, P 〈 0.025;79.6% vs 51.0%, P 〈 0.005）. The efficacy of combination therapy appeared to be better than interferon α2b group.
出处
《临床肝胆病杂志》
CAS
2005年第6期341-342,共2页
Journal of Clinical Hepatology
关键词
肝炎病毒
乙型
肝炎
慢性
干扰素
苦参素
胸腺肽Α1
药物疗法
联合
hepatitis B virus
hepatitis B, chronic
interferon α2b
marine
thymosin α1
drug therapy combination
